NEW YORK (TheStreet) -- Shares of Idera Pharmaceuticals (IDRA) soared more than 15% in late afternoon trading on Monday after the FDA granted orphan designation to the company's treatment of Waldenstrom's macroglobulinemia.
Waldenstrom's macroglobulinemia is a cancer of the B lymphocytes, a type of white blood cell, tied to an overproduction of proteins called IgM antibodies in the body.
The stock traded near its opening price of $4.01 for much of the day until approximately 3 p.m., at which time the stock skyrocketed.
Exclusive Report: Jim Cramer’s Best Stocks for 2015
Idera closed up $13.02% to $4.51 on Monday. More than 4.8 million shares changed hands, compared to the average volume of 1,415,580.IDRA data by YCharts